Chief Accounting Officer
Spero Therapeutics, Inc. (SPRO)Equibles does not estimate personal net worth.
Get an email with a short summary when Spero Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SPRO alertsSatyavrat Shukla is recorded as Chief Accounting Officer at Spero Therapeutics, Inc. (SPRO) since January 4, 2021. Spero Therapeutics, Inc. reported in an 8-K filed June 14, 2023 that Satyavrat Shukla was appointed member of the Board, effective August 1, 2023. Spero Therapeutics, Inc. reported in an 8-K filed June 14, 2023 that Satyavrat Shukla was appointed Chief Executive Officer and President, effective August 1, 2023. The proxy statement of Spero Therapeutics, Inc. reports total compensation of $2,025,178 for Satyavrat Shukla in fiscal 2025, including a base salary of $244,153. Disclosed compensation is on record for 6 fiscal years. Satyavrat Shukla has spoken on 2 earnings calls across 1 company, most recently for Spero Therapeutics, Inc. on January 9, 2023. Spero Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Spero Therapeutics, Inc. includes Esther Rajavelu (CEO, CFO and Board Member), Ankit Mahadevia, M.D. (Chairman), Frank E. Thomas (Chairman) and 7 others.
“the Board resolved to appoint Mr. Shukla to fill the newly created vacancy on the Board and to serve as a Class II director on the Board, effective as of the Transition Date.”
“Satyavrat Shukla, the Company's current Chief Financial Officer and Treasurer, was appointed by the Board to serve as Chief Executive Officer and President of the Company and as a member of the Board, in each case effective as of the Transition Date.”
“It is my pleasure to now provide an overview of Spero's financial results for the fourth quarter and full year ended December 31, 2022. Total revenues for the fourth quarter of 2022 were $47.4 million compared with revenues of $2.7 million for the fourth quarter of 2021.”
“I'd now like to turn your attention to our overview of Spero's financial results for the quarter ended June 30, 2021. Total revenues for the second quarter of 2021 were $5.1 million, compared with revenues of $1.7 million in the second quarter of 2020.”
2021-01-04–present
Start not stated–2024-04-16
Last confirmed by a filing; no departure on record
Start not stated–2022-08-05
Last confirmed by a filing; no departure on record
Start not stated–2025-04-28
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
Chief Accounting Officer
2021-01-04–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Spero Therapeutics, Inc. (SPRO) | Former President and Chief Executive Officer | $244,153 | $2,025,178 |
| 2024 | Spero Therapeutics, Inc. (SPRO) | Former President and Chief Executive Officer | $603,750 | $1,953,237 |
| 2023 | Spero Therapeutics, Inc. (SPRO) | Former President and Chief Executive Officer | $524,383 | $2,024,648 |
| 2022 | Spero Therapeutics, Inc. (SPRO) | President and Chief Executive Officer | $478,333 | $1,673,070 |
| 2021 | Spero Therapeutics, Inc. (SPRO) | President and Chief Executive Officer and Former Chief Financial Officer and Treasurer | $440,889 | $2,228,271 |
| 2020 | Spero Therapeutics, Inc. (SPRO) | Chief Financial Officer | — | — |
